See more : LCY Technology Corp. (4989.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Daiichi Sankyo Company, Limited (4568.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Daiichi Sankyo Company, Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Aventura Group AB (publ) (AVENT-B.ST) Income Statement Analysis – Financial Results
- JIANGXI BESTOO ENE (001376.SZ) Income Statement Analysis – Financial Results
- Zhixin Group Holding Limited (ZHIXF) Income Statement Analysis – Financial Results
- SEYOUNG D&C CO LTD (SFTXF) Income Statement Analysis – Financial Results
- Nano-X Imaging Ltd. (NNOX) Income Statement Analysis – Financial Results
Daiichi Sankyo Company, Limited (4568.T)
About Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,601.69B | 1,278.48B | 1,044.89B | 962.52B | 981.79B | 929.72B | 960.20B | 955.12B | 986.45B | 919.37B | 1,118.24B | 997.85B | 938.68B | 967.37B | 952.11B | 842.15B | 880.12B | 929.51B | 925.92B | 587.83B | 596.35B | 569.93B | 548.89B | 545.07B | 589.73B |
| Cost of Revenue | 415.32B | 363.53B | 353.33B | 338.29B | 343.21B | 364.61B | 346.02B | 349.37B | 318.62B | 323.09B | 402.29B | 313.66B | 268.61B | 281.68B | 278.03B | 214.40B | 234.57B | 265.20B | 290.74B | 213.89B | 221.65B | 228.75B | 221.44B | 222.99B | 234.78B |
| Gross Profit | 1,186.37B | 914.95B | 691.56B | 624.23B | 638.59B | 565.11B | 614.17B | 605.75B | 667.82B | 596.29B | 715.95B | 684.20B | 670.07B | 685.69B | 674.07B | 627.75B | 645.55B | 664.31B | 635.18B | 373.94B | 374.69B | 341.17B | 327.45B | 322.08B | 354.95B |
| Gross Profit Ratio | 74.07% | 71.57% | 66.19% | 64.85% | 65.04% | 60.78% | 63.96% | 63.42% | 67.70% | 64.86% | 64.02% | 68.57% | 71.38% | 70.88% | 70.80% | 74.54% | 73.35% | 71.47% | 68.60% | 63.61% | 62.83% | 59.86% | 59.66% | 59.09% | 60.19% |
| Research & Development | 365.17B | 341.57B | 260.23B | 227.35B | 197.47B | 203.71B | 236.05B | 214.35B | 208.66B | 190.67B | 191.21B | 183.05B | 185.05B | 194.33B | 196.80B | 184.54B | 163.47B | 170.66B | 158.72B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 637.00B | 471.22B | 358.31B | 333.08B | 302.32B | 277.70B | 301.85B | 302.48B | 328.76B | 331.20B | 413.19B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 325.25B | 357.33B | 321.74B | 289.02B | 279.14B | 261.34B | 246.80B | 234.29B | 212.24B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 96.77B | 95.69B | 99.65B | 105.75B | 109.80B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 637.00B | 471.22B | 358.31B | 333.08B | 302.32B | 277.70B | 301.85B | 302.48B | 328.76B | 331.20B | 413.19B | 96.77B | 95.69B | 99.65B | 105.75B | 109.80B | 325.25B | 357.33B | 321.74B | 289.02B | 279.14B | 261.34B | 246.80B | 234.29B | 212.24B |
| Other Expenses | -27.39B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57B | 3.64B | 3.72B | 3.26B | 67.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 974.78B | 794.37B | 618.54B | 560.43B | 499.79B | 481.41B | 537.89B | 516.82B | 537.41B | 521.86B | 604.40B | 584.14B | 402.36B | 415.15B | 425.01B | 396.04B | 488.72B | 524.38B | 479.30B | 289.02B | 279.14B | 261.34B | 246.80B | 234.29B | 212.24B |
| Cost & Expenses | 1,390.10B | 1,157.90B | 971.87B | 898.72B | 842.99B | 846.01B | 883.91B | 866.20B | 856.03B | 844.95B | 1,006.69B | 897.79B | 670.97B | 696.82B | 703.04B | 610.44B | 723.29B | 789.58B | 770.04B | 502.91B | 500.79B | 490.09B | 468.24B | 457.28B | 447.02B |
| Interest Income | 31.49B | 14.77B | 6.11B | 12.92B | 9.85B | 8.14B | 8.64B | 6.41B | 5.29B | 9.60B | 16.58B | 4.55B | 2.84B | 3.98B | 3.78B | 6.33B | 8.58B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.03B | 8.48B | 5.75B | 2.76B | 7.81B | 5.91B | 4.22B | 7.71B | 13.03B | 3.16B | 26.93B | 4.22B | 3.71B | 5.52B | 5.72B | 1.92B | 128.00M | 252.00M | 313.00M | 358.00M | 336.00M | 438.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 64.22B | 67.79B | 67.72B | 57.38B | 52.61B | 46.17B | 46.68B | 47.37B | 44.31B | 42.02B | 51.49B | 52.54B | 57.38B | 55.21B | 55.09B | 415.57B | 42.33B | 43.58B | 41.13B | 29.19B | 28.15B | 25.86B | 1.00M | 1.00M | 2.00M |
| EBITDA | 305.46B | 169.72B | 143.05B | 121.18B | 191.41B | 129.88B | 122.96B | 136.30B | 174.72B | 116.45B | 163.41B | 148.37B | 95.01B | 179.03B | 157.91B | 109.23B | 205.72B | 170.75B | 178.33B | 106.85B | 123.70B | 105.69B | 80.65B | 87.79B | 142.71B |
| EBITDA Ratio | 19.07% | 15.89% | 13.16% | 13.95% | 20.53% | 14.83% | 13.74% | 14.96% | 18.22% | 13.61% | 15.93% | 14.94% | 34.44% | 34.09% | 31.54% | 75.52% | 22.66% | 27.01% | 21.94% | 19.41% | 20.74% | 18.55% | 14.69% | 16.11% | 24.20% |
| Operating Income | 211.59B | 120.58B | 73.03B | 63.80B | 138.80B | 83.71B | 76.28B | 88.93B | 130.41B | 74.42B | 111.55B | 100.52B | 98.20B | 122.14B | 95.51B | 88.87B | 156.83B | 136.31B | 154.73B | 84.93B | 95.56B | 79.84B | 80.65B | 87.79B | 142.71B |
| Operating Income Ratio | 13.21% | 9.43% | 6.99% | 6.63% | 14.14% | 9.00% | 7.94% | 9.31% | 13.22% | 8.09% | 9.98% | 10.07% | 10.46% | 12.63% | 10.03% | 10.55% | 17.82% | 14.67% | 16.71% | 14.45% | 16.02% | 14.01% | 14.69% | 16.11% | 24.20% |
| Total Other Income/Expenses | 25.65B | 24.69B | 362.00M | -53.47B | -136.44B | -81.58B | -71.54B | -1.14B | -31.67B | -68.91B | -17.16B | -4.66B | -64.29B | -1.72B | 1.86B | -397.13B | 10.03B | -9.40B | -17.84B | -7.25B | -12.96B | -7.48B | 75.00M | -4.58B | -49.89B |
| Income Before Tax | 237.23B | 126.85B | 73.52B | 74.12B | 141.16B | 85.83B | 81.02B | 87.79B | 122.39B | 79.94B | 99.78B | 92.10B | 33.92B | 120.42B | 97.37B | -308.26B | 166.86B | 126.91B | 136.89B | 77.68B | 82.59B | 72.35B | 80.72B | 83.21B | 92.82B |
| Income Before Tax Ratio | 14.81% | 9.92% | 7.04% | 7.70% | 14.38% | 9.23% | 8.44% | 9.19% | 12.41% | 8.69% | 8.92% | 9.23% | 3.61% | 12.45% | 10.23% | -36.60% | 18.96% | 13.65% | 14.78% | 13.21% | 13.85% | 12.70% | 14.71% | 15.27% | 15.74% |
| Income Tax Expense | 36.22B | 17.67B | 6.54B | -1.71B | 12.20B | -7.59B | 21.21B | 40.31B | 41.99B | 36.37B | 46.42B | 23.90B | 39.76B | 41.81B | 50.02B | -79.17B | 69.10B | 48.08B | 49.20B | 28.67B | 38.66B | 38.16B | 41.93B | 40.74B | 50.00B |
| Net Income | 200.73B | 109.19B | 66.97B | 75.96B | 129.07B | 93.41B | 60.28B | 53.47B | 82.28B | 322.12B | 60.94B | 66.62B | 10.38B | 70.12B | 41.85B | -215.50B | 97.66B | 78.55B | 87.69B | 48.28B | 43.41B | 33.85B | 38.80B | 42.48B | 42.82B |
| Net Income Ratio | 12.53% | 8.54% | 6.41% | 7.89% | 13.15% | 10.05% | 6.28% | 5.60% | 8.34% | 35.04% | 5.45% | 6.68% | 1.11% | 7.25% | 4.40% | -25.59% | 11.10% | 8.45% | 9.47% | 8.21% | 7.28% | 5.94% | 7.07% | 7.79% | 7.26% |
| EPS | 104.69 | 56.96 | 34.94 | 39.17 | 66.40 | 48.07 | 30.44 | 26.54 | 39.79 | 152.52 | 28.86 | 30.32 | 4.92 | 33.21 | 19.82 | -101.41 | 45.12 | 35.92 | 39.83 | 37.26 | 32.86 | 25.28 | 28.59 | 31.09 | 31.11 |
| EPS Diluted | 104.62 | 56.91 | 34.91 | 39.11 | 66.27 | 47.96 | 30.37 | 26.48 | 39.70 | 152.21 | 28.80 | 30.27 | 4.91 | 33.17 | 19.81 | -101.41 | 45.12 | 35.92 | 39.82 | 37.26 | 32.86 | 25.28 | 28.59 | 31.09 | 31.11 |
| Weighted Avg Shares Out | 1.92B | 1.92B | 1.92B | 1.94B | 1.94B | 1.94B | 1.98B | 2.01B | 2.07B | 2.11B | 2.11B | 2.11B | 2.11B | 2.11B | 2.11B | 2.13B | 2.16B | 2.19B | 2.20B | 1.30B | 1.32B | 1.34B | 1.36B | 1.37B | 1.38B |
| Weighted Avg Shares Out (Dil) | 1.92B | 1.92B | 1.92B | 1.94B | 1.95B | 1.95B | 1.99B | 2.02B | 2.07B | 2.12B | 2.12B | 2.12B | 2.11B | 2.11B | 2.11B | 2.13B | 2.16B | 2.19B | 2.20B | 1.30B | 1.32B | 1.34B | 1.36B | 1.37B | 1.38B |
Source: https://incomestatements.info
Category: Stock Reports